Agilent Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agilent Technologies, Inc.
The UK company is developing oncology panels for non-small cell lung cancer.
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker, including a PMA supplement for Agilent’s PD-L1 IHC 22C3 pharmDx companion diagnostic for Merck’s Keytruda (pembrolizumab), an anti-PD-1 drug, for patients with head and neck squamous cell carcinoma. The US FDA also approved a supplement for the Cochlear Nucleus Profile Plus Series Cochlear Implant, designed to be safe with magnetic resonance imaging.
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
- Chiral Chemistry
- Diagnostic Equipment & Supplies
- Other Names / Subsidiaries
- ACEA Biosciences
- Advanced Analytical Technologies
- J&W Scientific Inc.
- Lasergen, Inc.
- Luxcel Biosciences
- Seahorse Bioscience
- Silicon Genetics
- Ultra Scientific